Applying clinical natural language processing to lung cancer in Spain: a terminology-based panel approach

Background We present a novel methodological framework for developing and validating a terminology-based Disease Panel to identify and characterize patients with metastatic non-small-cell lung cancer (mNSCLC) in a Spanish cohort by applying clinical natural language processing (cNLP) to electronic health records (EHRs). Materials and methods The mNSCLC Disease Panel was built from standardized vocabularies (Systematized Nomenclature of Medicine–Clinical Terms and Anatomical Therapeutic Chemical) enriched with curated alternative expressions such as synonyms, acronyms, and abbreviations. Terms were organized by clinical relevance and refined through clinical expert annotation. Using EHRead® (Medsavana S.L., Madrid, Spain), a cNLP pipeline, clinical concepts from the Disease Panel were extracted from Spanish EHRs. Performance was validated by clinical experts through the assessment of precision, recall, and F1 scores. Results The Disease Panel comprised 268 terms (mean of alternative expressions 8.4, range 1-41), including 125 (46.6%) demographic and clinical characteristics, 115 (42.9%) treatments, and 28 (10.5%) outcomes. The mean ± standard deviation (SD) precision across all terms was 0.97 ± 0.04, with values of 0.98 ± 0.04 for characteristics, 0.97 ± 0.04 for treatments, and 0.96 ± 0.06 for outcomes. For key terms, the mean ± SD precision, recall, and F1 score were 0.94 ± 0.05, 0.91 ± 0.08, and 0.92 ± 0.05, respectively. Conclusions This is the first validated terminology-based Disease Panel specifically designed for mNSCLC and integrated into a cNLP pipeline. It reliably identifies key clinical features with excellent extraction performance, supporting scalable real-world evidence generation. This approach offers a robust alternative to manual chart review or ‘International Classification of Diseases' data/claims data in oncology research.

Paper

The full text of this publication is not hosted on 44B due to licensing.

Read it at OpenAlex

Similar papers

© 2026 NYSGPT2525 LLC